References
- Skert C, Patriarca F, Sperotto A, Cerno M, Fili C, Zaja F, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoitic stem cell transplantation. Haematologica 2006; 91: 258–261
- Sfikakis P P, Gorgoulis V G, Katsiari C G, Evangelou K, Kostopoulos C, Black C M. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008; 47: 735–737
- van Daele P LA, Dik W A, Thio H B, van Hal P Th, van Laar J Am, Hooijkaas H, et al. Is imatinib mesylate a promising drug in sytemic sclerosis?. Arthritis Rheum 2008; 58: 2549–2552
- Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
- Daniels C E, Wilkes M C, Edens M, Kottom T J, Murphy S J, Limper A H, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308–1316
- Wang S, Wilkes M C, Leof E B, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 2005; 19: 1–11
- Rajkumar V S, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M, et al. Platelet-derived growth factor-β receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol 2006; 169: 2254–2265
- Buchdunger E, Cioffi C L, Law N, Stover D, Ohno-Jones S, Druker B J, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145
- Distler J HW, Jungel A, Huber L C, Schulze-Horsel U, Zwerina J, Gay R E, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311–322
- Banovic T, MacDonald K P, Morris E S, Rowe V, Kuns R, Don A, et al. TGF-β in allogeneic stem cell transplantation: friend or foe?. Blood 2005; 106: 2206–2214
- Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237–241
- Baroni S S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667–2676
- Clements P J, Lachenbruch P A, Seibold J R, Zee B, Steen V D, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892–1896
- Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis P K, Constantinides C, et al. E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol 2008; 61: 601–605
- Magro L, Catteau B, Coiteux V, Bruno B, Jouet J P, Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refracory sclerodermatous GVHD. Bone Marrow Transplant 2008; 42: 757–760
- Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22: 2214–2222